TO THE EDITOR
In acute leukaemia, p15/p16 (CDKN2) deletions have been found with high frequencies in both adult and childhood acute lymphoblastic leukaemia (ALL) (430%). In acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML) and myelodysplastic syndromes (MDS), very low frequencies of p15/p16 deletions have been observed (0-1%). However, the rates of p15 promoter hypermethylation, another frequent mechanism of p15/p16 inactivation, are very high in AML (70%), MDS (40%) and also precursor B-ALL and T-ALL (40%). 1 Therefore, inactivation of this locus is thought to play an important role in leukaemogenesis and could have important clinical significance.
The publications on the prognostic value of CDKN2 inactivation in acute leukaemia show contradictory results. 1 In most of these studies, however, no difference was made between childhood ALL cases with B-and T-cell phenotype. The reported poor prognostic value of CDKN2 deletions in some of these studies may result from differences in patient groups, as T-ALL in general has a worse outcome and a high incidence of CDKN2 deletions. 1 As the clinical relevance of CDKN2 deletions is still a subject of debate, we investigated, in a single centre study, the prognostic significance of CDKN2 deletions in 109 diagnostic childhood common/precursor B (c/pre-B)-ALL cases from the Erasmus MC, Sophia Children's Hospital using FISH analysis. A summary of the patients' characteristics is given in Table 1 . At diagnosis, informed consent of the patients and/or parents/guardians was obtained to use left-over material for research purposes.
Loss of CDKN2 was analysed using P1.1063 (53 kb), which spans most of the locus, covering the region from upstream exon 2 of p15 to distal to exon 2 of p16, including the coding sequence of p14.
2 If a deletion was observed, it was further characterized using a combination of P1.1062 and cos5. These probes cover both p15 and p16, but differ from P1.1063 in that P1.1062 (51 kb) starts upstream of p15 and ends immediately downstream of p16. Cos5 encompasses p15 and exons 1-2 of p16 and p14, and because of its smaller size (23 kb), smaller deletions may be detected. 2 All cases had also been analysed for the presence of cytogenetic aberrations.
Cytogenetic abnormalities were observed in 96/109 (88%) c/ pre-B-ALL cases. The remainder had apparently normal karyotypes, except for one case with karyotype failure due to lack of metaphases. The cytogenetic findings are summarized in Table 2 . The known poor prognostic aberrations, t(9;22) and 11q23 rearrangements, were grouped together (Table 1) , because the numbers were too few to use the individual translocations as a factor in survival analysis.
Loss of CDKN2 (both p15 and p16) was observed in 37/109 (34%) c/pre-B-ALL cases using P1.1063 and the combination of P1.1062 and cos5, whereas the other 72/109 (66%) were normal for this locus. Of these cases with CDKN2 loss, 7/37 (19%) had hemizygous deletions (loss of the CDKN2 FISH signal of one chromosome 9, with the signal on the other chromosome 9 being retained), whereas homozygous deletions (loss of CDKN2 FISH signals of both chromosomes 9) were observed in 15/37 (40%) cases. Additionally, we observed the presence of both hemi-and homozygous deletions in 15/37 (40%) cases (Table 2 ). In seven cases, both types of CDKN2 deletions were observed in 20-25% of the nuclei each. In three cases, the percentage of cells with a homozygous deletion was much higher than those with a hemizygous deletion (58-61 vs 18-20%, respectively), whereas in three other cases, hemizygous deletions were observed in higher percentages than homozygous deletions (50-74 vs 17-21%, respectively). In two cases, both hemi-and homozygous deletions were observed in 40-50% of the nuclei. The group with mixed deletions shows that different clones occur next to each other. This also demonstrates the heterogeneity in leukaemic samples. The percentage of deletions (34%) observed in our study is higher than that reviewed in Drexler 1 (23% for both p15 and p16), but comparable to other studies in which CDKN2 deletions have been observed in approximately 30% of B-lineage ALLs.
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The FISH results were compared to the corresponding karyotypes (Table 3 ). In total, only 18 cases had cytogenetically visible aberrations of the short arm of chromosome 9 ( Table 4) . Five of these cases had breakpoints in 9p21 (cases 1-5), whereas the remaining 13 cases (cases 6-18) showed breakpoints in other bands of 9p. Only 2/5 cases with 9p21 breakpoints showed CDKN2 deletions with FISH (cases 4 and 5), resulting either from deletions or unbalanced translocations as observed in the karyotype. The other 3/5 cases, having cytogenetically visible deletions or a translocation involving 9p21, did not have CDKN2 deletions (cases 1-3). In addition, 12/13 cases with abnormalities of the short arm of chromosome 9 other than 9p21 showed CDKN2 deletions (cases 7-18). Among the cytogenetically visible aberrations were dic(9;20)(p11-13;q11) in four cases (cases 7, 12, 15 and 16), a dic(9;10)(p13;p1?1) (case 8), unbalanced translocations with breakpoint in 9p13 or 9p2? in two cases (cases 13 and 18), additions to 9p1?2, p2?2 or p1 in three cases (cases 9-11), a del(9)(p?) in case 14 and a 9?p in case 17. In 6/12 cases, homozygous CDKN2 deletions were observed. Deletion of the second allele has occurred, which was not expected based on the karyotypic information. The remaining case in this category with a dic(9;10)(p?13;q?21) had no CDKN2 deletion (case 6). The other 23/37 cases with CDKN2 deletions showed no aberrations of 9p, indicating that CDKN2 deletions mostly are cryptic abnormalities. Thus, CDKN2 deletions occurred in patients with abnormal and normal karyotypes with and without cytogenetic 9p abnormalities.
We also investigated the association of CDKN2 deletions with specific cytogenetic abnormalities. The two diagnostic 11q23 rearranged c/pre-B-ALL samples showed no CDKN2 deletions, but a childhood secondary AML case with t(1;11)(p3?2;q23) involving MLL did. None of our three t(1;19)(q23;p13.3)-positive cases showed CDKN2 deletions, confirming the finding of Maloney et al 5 that CDKN2 deletions and t(1;19)(q23;p13.3) might be mutually exclusive. Both t(9;22)(q34;q11)-positive cases did have CDKN2 deletions (one homozygous, one mixed), as well as 7/25 t(12;21)(p13;q22) positive (four hemizygous, three homozygous) and 12/41 hyperdiploid (450 chromosomes) cases, indicating that t(9;22)(q34;q11), t(12;21)(p13;q22) or hyperdiploidy and CDKN2 deletions are not mutually exclusive.
For 17 patients, CDKN2 status could be analysed both at diagnosis and relapse (Table 5 ). In addition, one case developed secondary AML that could be analysed as well. In three cases, CDKN2 status differed between diagnostic and first relapse samples: two cases showed no CDKN2 deletions at diagnosis, whereas the relapse samples did. The third case showed a hemizygous deletion at diagnosis, and a homozygous deletion at relapse. In another case for which bone marrow at diagnosis, first and second relapse was available, no deletion was observed in diagnostic and first relapse samples, but in the second relapse sample a homozygous CDKN2 deletion was observed (Table 5) . Additionally, the case with secondary AML did not have CDKN2 deletions at diagnosis, but showed a mixed-type deletion when t-AML was diagnosed. Carter et al, 6 like earlier studies, observed increasing CDKN2 loss in 8/22 diagnosis-relapse couples. Based on this, they suggested that CDKN2 deletions might be important in disease progression. In 13/17 c/pre-B-ALL couples that we analysed, however, no differences were observed between diagnosis and relapse. Thus, in most cases, CDKN2 deletions did not represent an additional hit for disease progression.
Before starting survival analyses, correlations between any type of CDKN2 deletion and sex, age, leucocyte count (WBC), the presence of prognostic important chromosome abnormalities and treatment protocol were evaluated. Using Fisher's exact test, we did not observe any significant P-values for the different variables analysed (data not shown). The known poor prognostic factors (male gender, age X10 years old, t(9;22) and 11q23 rearrangements) did indeed correlate with worse clinical outcome (Pp0.05 for each factor). In all, 19/109 (17%) cases were treated according to Dutch Childhood Oncology Group (DCOG) treatment protocol ALL8 and 90/109 (83%) according to ALL9. No differences in clinical outcome was observed between the patients treated according to either protocol.
Next, univariate Cox's regression survival analysis was performed with stratification for treatment protocol. Diseasefree survival (DFS) was defined as the time from first diagnosis until a leukaemia-related event (nonresponse or relapse). Overall survival (OS) was defined as the time from first diagnosis until death. The median follow-up time for patients at risk for DFS was 4.8 years, and 5.1 years for OS. Univariate analysis showed that the probability of DFS (pDFS) of cases with CDKN2 deletions did not differ significantly from those without deletions (hazard ratio ¼ 1.293, 95% confidence interval (CI) ¼ 0.574-2.913, P ¼ 0.535). The 4-year pDFS was 74.276.5% for cases without deletions and 73.178.9% for cases with CDKN2 deletions (Figure 1 ). The 4-year pOS was not significantly different either: 86.874.9% for cases without deletions vs 79.878.0% for cases with CDKN2 deletions (hazard Bold ¼ discrepant cases. ratio ¼ 1.489, 95% CI ¼ 0.574-3.866, P ¼ 0.413). Using multivariate Cox's regression to correct for other prognostic factors, loss of CDKN2 was not an independent prognostic factor in either DFS (hazard ratio ¼ 1.251, 95% CI ¼ 0.532-2.941, P ¼ 0.608) or OS (hazard ratio ¼ 1.254, 95% CI ¼ 0.469-3.353, P ¼ 0.652). In most of the previous studies, no difference was made between childhood ALL cases with B-and T-cell phenotype. 1 The reported poor prognostic value of CDKN2 deletions in some of these studies may result from differences in patient groups, as T-ALL in general has a worse outcome and a high incidence of CDKN2 deletions.
1 Therefore, we investigated a group of 109 childhood c/pre-B-ALL cases only.
In most of the studies mentioned above, the presence of CDKN2 deletions was investigated using Southern blot, RT-PCR or loss of heterozygosity analysis. Using these techniques, CDKN2 deletions might be missed, as tumour heterogeneity can only partly be detected and small aberrant, homozygous deleted populations can be missed easily. With both Southern blotting and FISH, very small deletions might be missed depending on the size of probes used, but unlike Southern blotting, FISH can detect tumour heterogeneity of small subclones. We did not Figure 1 DFS in 109 c/pre-B-ALL cases with and without CDKN2 deletions. DFS survival curves of 72 cases without CDKN2 deletions and 37 cases with CDKN2 deletions. On the X-axis, time from initial diagnosis (in years) is depicted, and on the Y-axis, the probability of DFS.
Correspondence investigate the other frequent mechanism through which CDKN2 can be inactivated, promoter hypermethylation, as no DNA was available in most cases. Earlier studies investigating hypermethylation of p15 also showed contradictory clinical outcomes. However, also in most of these studies, no difference between B-and T-ALL phenotype was made either.
We investigated the occurrence of homo-and hemizygous deletions, but we did not examine the prognostic value of these types of deletions separately, because we considered the groups for the different types of deletions too small to reach statistical significance. Heyman et al, 7 however, showed, in a small group (n ¼ 24 for homozygous deletions, n ¼ 12 for hemizygous deletions), a difference in prognostic value between homoand hemizygous deletions using Southern blot combined with microsatellite analysis. 7 Future investigations on larger patient groups will have to provide more insight into the prognostic value of each type of deletion.
In conclusion, we observed three types of CDKN2 deletions, homozygous, hemizygous and mixed hemi/homozygous in 34% of 109 c/pre-B-ALL cases. The presence of CDKN2 deletions had no probable prognostic value in 109 childhood c/pre-B-ALL cases analysed in this single-centre study. No difference in CDKN2 status was observed between diagnosis and relapse in 76% of diagnosis-relapse couples. However, the incidence of CDKN2 deletions in c/pre-B-ALL (34%) suggests that the genes harboured at the CDKN2 locus might play an important role in leukaemogenesis not only in T-ALL but also in precursor B-ALL.
